SpliceBio Highlights Lead Gene Therapy Program Targeting Stargardt Disease

According to a recent LinkedIn post from SpliceBio, the company is drawing attention to Stargardt disease, a progressive retinal disorder that leads to central vision loss and can progress to blindness. The post notes that the condition is caused by biallelic mutations in the ABCA4 gene and currently represents a substantial unmet medical need, with no approved treatments available.

The LinkedIn post highlights SpliceBio’s lead program, SB-007, which is described as being designed to address the underlying genetic cause of Stargardt disease by restoring expression of a functional, full-length ABCA4 protein in the retina. The content further suggests that this approach could potentially treat patients across all ABCA4 mutations and directs readers to a podcast episode on The BioHub Podcast for more details.

For investors, this emphasis on SB-007 underscores SpliceBio’s strategic focus on gene therapy solutions for inherited retinal diseases, positioning the program as a key value driver in the company’s pipeline. If the therapy can demonstrate clinical efficacy and safety across a broad range of ABCA4 mutations, it could expand the addressable patient population and strengthen the company’s competitive stance in the ophthalmology and gene therapy markets. At the same time, the lack of existing approved treatments highlights both the potential market opportunity and the development risk inherent in pioneering therapies in an area with limited clinical precedent.